Pascal Soriot, COO Roche Pharmaceuticals - PDF by sus16053

VIEWS: 0 PAGES: 9

									Annual Media Conference
3 February 2010
 Pascal Soriot, COO Roche Pharmaceuticals




                                            1
Sales 2009: Growing above the market



                                     2008     2009    % change in
                                    CHF m    CHF m    CHF local*

         Pharmaceuticals Division   35,961   38,996    +8    +11
             United States          14,029   14,805    +6     +5
             Western Europe         10,330   10,827    +5    +12
             Japan                   3,336    4,765   +43    +29
             International           8,266    8,599    +4    +13




*local currencies
                                                                    2
2009: Pharma Division
Strong profit increase driven by sales and moderate cost growth

                                                   2009                              2009 vs. 2008
                                               CHF m % sales                          local growth
    Sales                                     38,996             100.0                            11%              +8% in CHF

      Royalties & other op inc                  1,948                  5.0    -10%
      Cost of sales                           -9,535             -24.4                      6%            COGS & PC2:
                                                                                                          +11%
      M&D                                     -6,964             -17.9                     6%
      R&D                                     -8,896             -22.8                                13% Excl.
                                                                                                          impairments: +11%
                                                                                        Administration:
      G&A                                     -1,395                  -3.6   -11%
                                                                                        -13%


    Operating profit1                         14,154                  36.3                                15%      +9% in CHF



1   before exceptional items   2   Cost of goods sold & period cost                                                           3
Oncology franchise exceeds CHF 20 billion in sales


Oncology sales                         local growth
(CHF bn)                                 +8 %
20.0
                                                +13 %   Avastin

                                                 +9 %   -   growing in all indications
16.0



12.0                                                    MabThera
                                                 +8%
                                                        - driven by use in CLL
 8.0                                                    - future growth in maintenance therapy

 4.0
                                                 +6 %   Emerging markets offer additional potential

 0.0
       2005   2006      2007    2008     2009
                                                        Strong pipeline
        US                     Western Europe
        International          Japan

                                                                                                      4
All oncology brands on continued growth path
New indications driving growth

  Sales growth by region (%) in LC                          Proportional sales
 35
       +21%                                          100%

 30    31

 25                                    Ex US
                                       US
 20                                                  50%
                  +10%

 15                        +6%             +8%
            14   14
                                                                                                                               Ex US
 10
                                                                                                                               US
                            9             9
  5
                      5
                                 3             4                    pt
                                                                       in           va                       xa
                                                                                                               n
                                                                                                                       st i
                                                                                                                           n
                                                                  ce          rce                     Rit
                                                                                                         u           va
  0                                                         H   er          Ta                     a/
                                                                                                                   A
                                                                                                  r
                                                                                               he
       Avastin   Tarceva   MabThera/     Herceptin                                        a bT
                            Rituxan                                                      M

                                                                                                                               5
Inflammation/Autoimmune/Transplantation
MabThera in RA on continued growth path, CellCept US patent expiry

  Sales                          local growth
(CHF bn)
3.5
                          -6%
3.0
                                   +37 %
                                                Actemra
2.5                                             - EU approval Jan 2009; good sales development
                                   +13 %        - US: approval Jan 2010
2.0

1.5
                                    +3 %        CellCept
1.0                                             - sales (-22%); US patent expiry

0.5                                 -28 %       MabThera RA
                                                - continued progression
0.0
      2005 2006 2007 2008 2009
      US                  Western Europe
      International       Japan

                                                                                             6
Virology: Tamiflu exceptional growth

                                                            Tamiflu quarterly sales (CHF m)
Major brands                 local growth
                                              1'200

                      +5 %                                                          Retail
 Pegasys                                      1'000
                                                                        Gov’ment Pandemic
                                                                                                                267   663
                                               800    119

               +6 %
Cymevene                           2009
Valcyte                                        600
                                   2008
                                                                        54                                260

                                               400
                                                      746                                                       727
                                   +435 %                                                           97


 Tamiflu                                                    460   65    458
                                                                                                                      533

                                               200
                                                                              233                         349
                                                                                              75    304
                                                                  192
                                                                                         65   106
                                                                              45    50   36
                                                 0
CHF bn 0       1      2        3          4           Q1    Q2    Q3    Q4    Q1    Q2   Q3   Q4    Q1    Q2    Q3    Q4
                                                      07    07    07    07    08    08   08   08    09    09    09    09



                                                                                                                           7
Late-stage pipeline continues to build up
Expanding into new therapeutic areas
   Number of NMEs                                                         Additional important Ph III
                                                                             decisions in 2010
   CNS
                                                                                       12
   Metabolic
                                                                                 ocrelizumab MS*
   Inflammation                                                10                   GlyT1 inh

                                                             GlyT1 inh             SGLT2 inh*
   Oncology
                                                            aleglitazar            aleglitazar

                                                           taspoglutide            taspoglutide

                                                            dalcetrapib            dalcetrapib

                                                            ocrelizumab          ocrelizumab RA
                                                 4         Hedgehog inh           Hedgehog inh
                                            taspoglutide   BRAF inhibitor         BRAF inhibitor

                                2           dalcetrapib       T-DM1                  T-DM1

                             ocrelizumab    ocrelizumab    RG7159 (CLL)         RG7159 (CLL, NHL)

                               Actemra      pertuzumab      pertuzumab             pertuzumab


                               2007           2008           2009                  2010E
* Go/no-go decision for phase III pending                                                               8
Pharma: Key objectives for 2010
                           Compound                      Phase          Indication
Major clinical news flow



                           Avastin                           III        Ovarian cancer, front line (GOG-0218, ICON-7)

                           Avastin                           III        Gastric cancer
                           Avastin                           III        Prostate cancer
                           Hedgehog inh                      II         mCRC proof of concept data
                           Pertuzumab early BC               II         Phase II data
                           Taspoglutide                      III        Phase III data presentation
                           Ocrelizumab RA                    III        Data in DMARD- and anti TNF-IRs
                           Ocrelizumab RRMS                  II         Full Phase II data and Ph III decision

                           Compound         Indication
                           Avastin          mBC 2nd line
                                                                                            Pharma Division Outlook 2010:
                           Avastin          Ovarian cancer front line
   Filings




                           Avastin          Gastric cancer                                  Mid single-digit sales growth
                           Mabthera         1st line maintenance iNHL                       excluding Tamiflu
                           Ocrelizumab      RA
                           Xeloda           Adj BC

                                                                                                                            9

								
To top